Anticoagulants in Older Patients with Nonvalvular Atrial Fibrillation after Intracranial Hemorrhage
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background and Purpose Patients with nonvalvular atrial fibrillation (NVAF) who survive an intracranial hemorrhage (ICH) have an increased risk of ischemic stroke and systemic embolism (IS/ SE). We investigated whether starting oral anticoagulants (OACs) among older NVAF patients after an ICH was associated with a lower risk of IS/SE and mortality but offset by an increase in major bleeding. Methods We assembled a patient cohort from the Quebec Régie de l’Assurance Maladie du Québec (RAMQ) and Med-Echo administrative databases. We identified older adults with NVAF from 1995 to 2015. All patients with incident ICH and discharged in community were included. Patients were categorized according to OAC exposure. Outcomes included IS/SE, all-cause mortality, recurrent ICH and major bleeding after a quarantine period of 6 weeks. Crude event rates were calculated at 1-year of follow-up, and Cox proportional hazard models with a time-dependent binary exposure were used to assess adjusted hazard ratios (AHRs). Results The cohort of 683 NVAF patients with ICH aged 83 years on average. The rates (per 100 person-years) for IS/SE, death, ICH and major bleeding were 3.3, 40.6, 11.4, and 2.7 for the no OAC group; and 2.6, 16.3, 5.2, and 5.2 for OAC group, respectively. The AHR for IS/SE and death was 0.10 (95% confidence interval [CI], 0.05 to 0.21), 0.43 (95% CI, 0.19 to 0.97) for recurrent ICH and 1.73 (95% CI, 0.71 to 4.20) for major extracranial bleeding comparing OAC exposure to non-exposed. Conclusions Initiating OAC after ICH in older individuals with NVAF is associated with a reduction of IS/SE and mortality and a trend in recurrent ICH supporting its use after ICH.
Abstract
Background and Purpose Patients with nonvalvular atrial fibrillation (NVAF) who survive an intracranial hemorrhage (ICH) have an increased risk of ischemic stroke and systemic embolism (IS/ SE). We investigated whether starting oral anticoagulants (OACs) among older NVAF patients after an ICH was associated with a lower risk of IS/SE and mortality but offset by an increase in major bleeding. Methods We assembled a patient cohort from the Quebec Régie de l’Assurance Maladie du Québec (RAMQ) and Med-Echo administrative databases. We identified older adults with NVAF from 1995 to 2015. All patients with incident ICH and discharged in community were included. Patients were categorized according to OAC exposure. Outcomes included IS/SE, all-cause mortality, recurrent ICH and major bleeding after a quarantine period of 6 weeks. Crude event rates were calculated at 1-year of follow-up, and Cox proportional hazard models with a time-dependent binary exposure were used to assess adjusted hazard ratios (AHRs). Results The cohort of 683 NVAF patients with ICH aged 83 years on average. The rates (per 100 person-years) for IS/SE, death, ICH and major bleeding were 3.3, 40.6, 11.4, and 2.7 for the no OAC group; and 2.6, 16.3, 5.2, and 5.2 for OAC group, respectively. The AHR for IS/SE and death was 0.10 (95% confidence interval [CI], 0.05 to 0.21), 0.43 (95% CI, 0.19 to 0.97) for recurrent ICH and 1.73 (95% CI, 0.71 to 4.20) for major extracranial bleeding comparing OAC exposure to non-exposed. Conclusions Initiating OAC after ICH in older individuals with NVAF is associated with a reduction of IS/SE and mortality and a trend in recurrent ICH supporting its use after ICH.
참고문헌 (27)
- Colilla S, "Estimates of current and future incidence and prevalence of atrial fibrillation in the U.S. adult population", Am J Cardiol, 112, pp.1142~1147 (2013)
- McGrath ER, "Association of atrial fibrillation with mortality and disability after ischemic stroke", Neurology, 81, pp.825~832 (2013)
- January CT, "2014 AHA", ACC, American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society, pp.J Am Coll Cardiol, 2014[DOI]
- Hart RG, "Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation", Ann Intern Med, 146, pp.857~867 (2007)
- Culebras A, "Summary of evidence-based guideline update: prevention of stroke in nonvalvular atrial fibrillation: report of the Guideline Development Subcommittee of the American Academy of Neurology", Neurology, 83, pp.1220~ (2014)
- Alonso A, "Intracranial hemorrhage mortality in atrial fibrillation patients treated with dabigatran or warfarin", Stroke, 45, pp.2286~2291 (2014)
- Hemphill JC 3rd, "Guidelines for the management of spontaneous intracerebral hemorrhage: a guideline for healthcare professionals from the American Heart Association", American Stroke Association, 2015, pp.46, 2032~2060
- Steiner T, "European Stroke Organisation (ESO)guidelines for the management of spontaneous intracerebral hemorrhage", Int J Stroke, 9, pp.840~855 (2014)
- Chao TF, "Use of oral anticoagulants for stroke prevention in patients with atrial fibrillation who have a history of intracranial hemorrhage", Circulation, 133, pp.1540~1547 (2016)
- Nielsen PB, "Restarting anticoagulant treatment after intracranial hemorrhage in patients with atrial fibrillation and the impact on recurrent stroke, mortality, and bleeding: a nationwide cohort study", Circulation, 132, pp.517~525 (2015)
- Kuramatsu JB, "Anticoagulant reversal, blood pressure levels, and anticoagulant resumption in patients with anticoagulation-related intracerebral hemorrhage", JAMA, 313, pp.824~836 (2015)
- Biffi A, "Oral anticoagulation and functional outcome after intracerebral hemorrhage", Ann Neurol, 82, pp.755~765 (2017)
- Murthy SB, "Restarting anticoagulant therapy after intracranial hemorrhage: a systematic review and meta-analysis", Stroke, 48, pp.1594~1600 (2017)
- Korompoki E, "Long-term antithrombotic treatment in intracranial hemorrhage survivors with atrial fibrillation", Neurology, 89, pp.687~696 (2017)
- Hawkes MA, "Anticoagulation for atrial fibrillation after intracranial hemorrhage: a systematic review", Neurol Clin Pract, 8, pp.48~57 (2018)
- Zhou Z, "Resuming anticoagulants after anticoagulation-associated intracranial haemorrhage: systematic review and meta-analysis", BMJ Open, 8, pp.e019672~ (2018)
- Nielsen PB, "Outcomes associated with resuming warfarin treatment after hemorrhagic stroke or traumatic intracranial hemorrhage in patients with atrial fibrillation", JAMA Intern Med, 177, pp.563~570 (2017)
- Poli D, "Recurrence of ICH after resumption of anticoagulation with VK antagonists: CHIRONE study", Neurology, 82, pp.1020~1026 (2014)
- Singer DE, "The net clinical benefit of warfarin anticoagulation in atrial fibrillation", Ann Intern Med, 151, pp.297~305 (2009)
- Lip GY, "Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation", Chest, 137, pp.263~272 (2010)
- Friberg L, "Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678patients with atrial fibrillation: the Swedish Atrial Fibrillation cohort study", Eur Heart J, 33, pp.1500~1510 (2012)
- Pisters R, "A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey", Chest, 138, pp.1093~1100 (2010)
- Deyo RA, "Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases", J Clin Epidemiol, 45, pp.613~619 (1992)
- Vanassche T, "Risk of ischaemic stroke according to pattern of atrial fibrillation: analysis of 6563 aspirin-treated patients in ACTIVE-A and AVERROES", Eur Heart J, 36, pp.281~287a (2015)
- Stoker TB, "Managing risk after intracerebral hemorrhage in concomitant atrial fibrillation and cerebral amyloid angiopathy", Stroke, 47, pp.e190~e192 (2016)
- Shen AY, "Racial", ethnic differences in the risk of intracranial hemorrhage among patients with atrial fibrillation, 2007, pp.50, 309~315
- van Nieuwenhuizen KM, "Apixaban versus Antiplatelet drugs or no antithrombotic drugs after anticoagulationassociated intraCerebral HaEmorrhage in patients with Atrial Fibrillation (APACHE-AF): study protocol for a randomised controlled trial", Trials, 16, pp.393~ (2015)